Harmony Biosciences reported net product revenue of $268.9 million for the third quarter of 2026, a 12.3% increase year-over-year. Net income for the nine months ended September 30, 2026, rose to $156.1 million compared to $136.2 million in the prior year, despite higher operating expenses driven by research and development.
Harmony Biosciences reported Q3 2026 financial results with WAKIX net revenue of $269 million, driven by 400 net patient additions. The company reaffirmed its full-year 2026 revenue guidance of $1.0 billion to $1.04 billion and announced that Peter Anastasiou will succeed Jeffrey Dayno as CEO effective January 1, 2027.
“As I prepare to transition the President and CEO role to Peter on January 1, I believe Harmony is operating from a position of strength, with a durable and growing WAKIX franchise, the financial flexibility to invest in innovation, conviction to pursue strategic business development opportunities, and a pipeline led by BP-205 that has the potential to generate significant long-term value.”
Jeffrey Dayno, MD, President and Chief Executive Officer
“I am proud of the talented team and passionate organization we have built, which position Harmony for continued success in delivering innovative treatments to patients and sustained value for our shareholders.”
Jeffrey Dayno, MD, President and Chief Executive Officer
Harmony Biosciences announced the compensation terms for its leadership succession plan, including a separation and consulting agreement for retiring CEO Jeffrey M. Dayno and an amended employment agreement for incoming CEO Peter Anastasiou. Dr. Dayno will serve as a non-executive advisor through January 2028 at a rate of $500 per hour with continued equity vesting, while Mr. Anastasiou's new terms as President and CEO take effect January 1, 2027.